Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Epworth Sleepiness Scale (ESS) Improvements: Solriamfetol demonstrated greater efficacy in reducing ESS scores than sodium oxybate (mean difference (MD) -2.56, 95% confidence interval (CI) -4.62 to -0.51) and pitolisant (MD -2.88, 95% CI -4.89 to -0.88).
• Maintenance of Wakefulness Test (MWT) Improvements: Solriamfetol showed a superior effect on MWT compared to pitolisant (standardized mean difference (SMD) 0.45, 95% CI 0.02 to 0.88) and modafinil (SMD 0.42, 95% CI 0.05 to 0.79).
• Narcolepsy Symptoms and Sleep Metrics: Sodium oxybate improved multiple narcolepsy symptoms, including cataplexy, daytime sleepiness, sleep latency, sleep stages, nocturnal awakenings, and quality of life, with no observed effect on stage 2 sleep (P = 0.88).
• Sodium Oxybate: Associated with dose-dependent adverse effects and is less well tolerated than placebo (relative risk (RR) = 6.08; 95% CI = 2.18 to 16.97; P = 0.0006). No cognitive impairments observed in clinical use; however, moderate recreational use can lead to acute cognitive impairments, and high-dose or multiple gamma-hydroxybutyrate acid (GHB)-induced comas may result in long-term cognitive impairments. High dependence potential and possible neurotoxic effects at elevated doses.
• Comparative Safety: While solriamfetol demonstrated superior efficacy, the overall efficacy-safety balance for sodium oxybate, pitolisant, and modafinil was more favorable than for solriamfetol.
• There is no population type or subgroup information available in the reviewed studies.